Gland Pharma (GLAND) Fundamentals 2026 — P/E 39.1x, Revenue Analysis | SniperIQ
Gland Pharma (GLAND) is a India-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₹40,223 Crore, trading at ₹2440.25 on the BSE. This SniperIQ fundamentals page covers Gland Pharma's valuation (P/E 39.1x, P/B 3.9x), profitability (net margin 16.0%), revenue (₹6,431 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Gland Pharma's market cap?
Gland Pharma (GLAND) has a market capitalization of approximately ₹40,223 Crore, trading at ₹2440.25 on the BSE. Market cap moves with the live share price.
What is Gland Pharma's P/E ratio?
Gland Pharma's trailing twelve-month P/E ratio is 39.1x, with a price-to-book (P/B) of 3.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Gland Pharma?
Gland Pharma runs a net profit margin of 16.0%, a gross margin of 30.0%, and an operating margin of 18.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Gland Pharma generate?
Gland Pharma reported revenue of ₹6,431 Crore for fiscal year 2026, with net income of ₹1,027 Crore and earnings per share (EPS) of 62.35. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Gland Pharma pay a dividend?
Gland Pharma offers a trailing dividend yield of about 1.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Gland Pharma financially healthy?
Gland Pharma carries a debt-to-equity ratio of 0.03x and a current ratio of 4.68x, with a market beta of 0.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Gland Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gland Pharma (GLAND) the key facts are: market cap ₹40,223 Crore, P/E 39.1x, revenue ₹6,431 Crore, 52-week range 1575-2574. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Gland Pharma's full fundamentals live
Get Gland Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.